Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-06 5:03 pm Purchase | 2024-02-01 | 13D | Cazoo Group Ltd CZOOF | VIKING GLOBAL INVESTORS LP | 2,142,728 43.800% | 2,121,301 (+9900.00%) | Filing History |
| 2024-09-30 4:29 pm Purchase | 2024-09-20 | 13G | BioMarin Pharmaceutical Inc. BMRN | VIKING GLOBAL INVESTORS LP | 9,753,293 5.100% | 9,753,293 (New Position) | Filing History |
| 2024-08-20 8:42 pm Unchanged | 2024-08-16 | 13D | BridgeBio Pharma, Inc. BBIO | VIKING GLOBAL INVESTORS LP | 25,120,991 13.400% | 0 (Unchanged) | Filing History |
| 2024-07-15 4:17 pm Purchase | 2024-07-03 | 13G | Longboard Pharmaceuticals, Inc. LBPH | VIKING GLOBAL INVESTORS LP | 1,752,656 5.200% | 1,752,656 (New Position) | Filing History |
| 2024-06-18 5:05 pm Sale | 2024-06-17 | 13G | APi Group Corporation APG | VIKING GLOBAL INVESTORS LP | 40,548,774 9.900% | -7,485,599 (-15.58%) | Filing History |
| 2024-06-07 4:23 pm Purchase | 2024-05-29 | 13G | Inhibrx Biosciences, Inc. INBX | VIKING GLOBAL INVESTORS LP | 1,787,705 12.300% | 1,787,705 (New Position) | Filing History |
| 2024-06-03 5:56 pm Sale | 2024-05-30 | 13G | Inhibrx Biosciences, Inc. INBX | VIKING GLOBAL INVESTORS LP | 0 0.000% | -7,150,826 (Position Closed) | Filing History |
| 2024-03-20 6:05 pm Purchase | 2024-03-18 | 13G | Standard BioTools Inc. LAB | VIKING GLOBAL INVESTORS LP | 58,651,170 15.300% | 29,544,805 (+101.51%) | Filing History |
| 2024-03-01 4:18 pm Sale | 2024-02-28 | 13G | APi Group Corporation APG | VIKING GLOBAL INVESTORS LP | 48,034,373 12.300% | -15,741,363 (-24.68%) | Filing History |
| 2024-02-28 4:28 pm Sale | 2024-02-26 | 13G | RayzeBio, Inc. Common Stock RYZB | VIKING GLOBAL INVESTORS LP | 0 0.000% | -6,642,700 (Position Closed) | Filing History |
| 2024-02-14 10:27 am Purchase | 2023-12-31 | 13G | Pharvaris N.V. PHVS | VIKING GLOBAL INVESTORS LP | 3,656,923 7.000% | 425,000 (+13.15%) | Filing History |
| 2024-02-14 10:26 am Purchase | 2023-12-31 | 13G | Edgewise Therapeutics, Inc. EWTX | VIKING GLOBAL INVESTORS LP | 6,159,146 9.700% | 1,750,000 (+39.69%) | Filing History |
| 2024-02-14 10:25 am Purchase | 2023-12-31 | 13G | APi Group Corporation APG | VIKING GLOBAL INVESTORS LP | 63,775,736 17.400% | 632,046 (+1.00%) | Filing History |
| 2024-02-14 10:24 am Sale | 2023-12-31 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | VIKING GLOBAL INVESTORS LP | 2,962,555 4.400% | -1,672,051 (-36.08%) | Filing History |
| 2024-02-14 10:23 am Unchanged | 2023-12-31 | 13G | Adaptive Biotechnologies Corporation ADPT | VIKING GLOBAL INVESTORS LP | 29,993,708 20.700% | 0 (Unchanged) | Filing History |
| 2024-02-14 10:21 am Purchase | 2023-12-31 | 13G | Trevi Therapeutics, Inc. TRVI | VIKING GLOBAL INVESTORS LP | 6,599,062 9.990% | 436,700 (+7.09%) | Filing History |
| 2024-02-14 10:20 am Sale | 2023-12-31 | 13G | Roivant Sciences Ltd. ROIV | VIKING GLOBAL INVESTORS LP | 69,368,961 8.600% | -5,869,739 (-7.80%) | Filing History |
| 2024-02-14 10:18 am Unchanged | 2023-12-31 | 13G | Rallybio Corporation RLYB | VIKING GLOBAL INVESTORS LP | 4,194,777 11.100% | 0 (Unchanged) | Filing History |
| 2024-02-14 10:17 am Sale | 2023-12-31 | 13G | PepGen Inc. PEPG | VIKING GLOBAL INVESTORS LP | 1,482,434 6.200% | -62,197 (-4.03%) | Filing History |
| 2024-02-14 10:16 am Unchanged | 2023-12-31 | 13G | Ginkgo Bioworks Holdings, Inc. DNA | VIKING GLOBAL INVESTORS LP | 3,577,128 8.800% | 0 (Unchanged) | Filing History |